配售价142.00港元较前一交易日收市价折让约[此处需补充前一交易日收市价数据才能计算折让比例]， 较前五个交易日平均收市价折让约[此处需补充前五个交易日平均收市价数据才能计算折让比例]。配售 股份占现有已发行股本约0.65%，完成后占扩大股本约0.65%。 重塑能源是一家能源集团公司，主营业务未详细提及。所得款项中，约3915万港元将用于通过偿还未偿 还银行贷款及租赁负债优化财务结构，约3915万港元用于一般公司用途。本次发行根据股东大会授予的 一般授权实施，已于2025年10月8日完成交割。 来源：新浪港股-好仓工作室 2025年10月8日，重塑能源（股份代号：2570）公告称，通过一般授权以配售新H股方式融资，发行 563,340股（约0.0亿股），募集约8000万港元（扣除费用后净得约7830万港元）。本次融资由中金公 司、招商证券国际担任联席整体协调人兼联席配售代理。 点击查看公告原文>> 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方 ...

Core Viewpoint - The Hong Kong stock market's innovative pharmaceutical sector has shown a significant rebound this year, with a notable increase in refinancing activities, reflecting the ambition of domestic innovative drug companies to expand globally and leverage differentiated innovation advantages [1] Group 1: Financing Activities - The total refinancing amount in the Hong Kong market reached HKD 173.8 billion in the first half of the year, a year-on-year increase of 227%, surpassing the total for the entire year of 2024 [1] - More than 10 innovative pharmaceutical companies in the Hong Kong market have conducted placement financing, indicating a strong demand for capital to support research and development [1] - The company Xiansheng Pharmaceutical announced a placement financing plan to raise approximately HKD 1.5535 billion by issuing 121 million shares, reflecting its strategic move during a critical development phase [2][5] Group 2: Pricing and Market Response - The placement price of HKD 12.95 per share represents an approximately 8.03% discount to the closing price on September 1, 2025, and a 6.67% discount to the average closing price over the previous five trading days, which is within the common discount range of 5%-10% for stock issuances in the Hong Kong market [5][6] - The issuance of 121 million new shares will account for approximately 4.66% of the expanded total issued share capital, balancing the company's financing needs with shareholder interests [6] - Following the announcement, the stock price of Xiansheng Pharmaceutical experienced short-term fluctuations, but the trading volume exceeded 180 million shares, setting a new record since its listing, indicating strong market interest [7] Group 3: Company Performance and Strategy - Xiansheng Pharmaceutical has transformed into a leading innovative drug company, with a reported revenue growth of 15.1% to HKD 3.585 billion and an adjusted net profit increase of 21.1% to HKD 651 million, driven primarily by its innovative drug business [8] - The company has launched ten innovative drugs, with revenue from these drugs reaching HKD 2.776 billion, a 26% increase, accounting for 77.4% of total revenue [8] - Approximately 90% of the funds raised from the placement will be allocated to research and development, focusing on core areas such as neurology, oncology, autoimmune diseases, and anti-infection, which will enhance the company's global pipeline and validate its Biopharma value [9]